Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Wednesday, September 24, 2014

Evotec and Its Partners Awarded Public Grants to Develop New Drug Candidates to Treat Multiple Sclerosis

HAMBURG, Germany, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Evotec AG   (ISIN:DE0005664809) announced today that it has entered into three novel research projects for the treatment of Multiple Sclerosis ("MS") supported by research funds from the German Federal Ministry of Education and Research ("BMBF").
The respective scientific approaches stem from the Deutsches Rheuma-Forschungszentrum ("DRFZ"; an institute of the Leibniz Association; Prof. A. Hamann) and the University Medical Center Hamburg-Eppendorf ("UKE"; Prof. M. Friese; Dr J. Herkel) comprising cytokine regulation, neuro-protection and tolerance induction.
Evotec will utilise its drug discovery platform, its project management capabilities and its market presence to identify drug candidates in these novel approaches to tackle MS and to commercialise those later on. Current MS treatments mostly constitute disease-modifying approaches while more specific or well-differentiated alternative treatment modes are eagerly looked for by the industry. The three projects have a term of between 1.5 and 3 years and comprise a total budget of about EURO 5 m.


~~~~~~~~~~~~~~~~~~~~
 Keep CURRENT and up to date, with MS News and Information
Sign-up for our Bi-Monthly eNewsletters 
.

WATCH OUR MS EDUCATIONAL VIDEOS by Topic, 

.


No comments: